Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon V Tiu

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
Radiation and Environmental Biophysics|December 17, 2013
Sex differences in the incidence of chronic myeloid leukemiaTomas Radivoyevitch, Gradimir M Jankovic, Ramon V Tiu, et al.
Blood|April 30, 2011
SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromesManuel G Afable, Marcin Wlodarski, Hideki Makishima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2018
Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell CarcinomaJohanna Bendell, Valerie Andre, Alan Ho, et al.
The Oncologist|June 26, 2023
Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United StatesEmily Nash Smyth, Jincy John, Ramon V Tiu, et al.
Blood|April 18, 2009
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasmsAnna M Jankowska, Hadrian Szpurka, Ramon V Tiu, et al.
Leukemia & Lymphoma|April 29, 2014
Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) countsAli Tabarroki, Yogen Saunthararajah, Valeria Visconte, et al.
Cancer|December 20, 2011
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)Nelli Bejanyan, Ramon V Tiu, Azra Raza, et al.
Leukemia & Lymphoma|May 8, 2013
Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidineYang Liu, Ali Tabarroki, Steven Billings, et al.
American Journal of Hematology|October 15, 2013
Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemiaMoshe C Ornstein, Sudipto Mukherjee, Sanjay Mohan, et al.
Leukemia Research|February 19, 2013
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidineLionel Adès, Mikkael A Sekeres, Alice Wolfromm, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
Radiation and Environmental Biophysics|December 17, 2013
Sex differences in the incidence of chronic myeloid leukemiaTomas Radivoyevitch, Gradimir M Jankovic, Ramon V Tiu, et al.
Blood|April 30, 2011
SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromesManuel G Afable, Marcin Wlodarski, Hideki Makishima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2018
Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell CarcinomaJohanna Bendell, Valerie Andre, Alan Ho, et al.
The Oncologist|June 26, 2023
Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United StatesEmily Nash Smyth, Jincy John, Ramon V Tiu, et al.
Blood|April 18, 2009
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasmsAnna M Jankowska, Hadrian Szpurka, Ramon V Tiu, et al.
Leukemia & Lymphoma|April 29, 2014
Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) countsAli Tabarroki, Yogen Saunthararajah, Valeria Visconte, et al.
Cancer|December 20, 2011
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)Nelli Bejanyan, Ramon V Tiu, Azra Raza, et al.
Leukemia & Lymphoma|May 8, 2013
Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidineYang Liu, Ali Tabarroki, Steven Billings, et al.
American Journal of Hematology|October 15, 2013
Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemiaMoshe C Ornstein, Sudipto Mukherjee, Sanjay Mohan, et al.
Leukemia Research|February 19, 2013
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidineLionel Adès, Mikkael A Sekeres, Alice Wolfromm, et al.
Pageof 9